
Accretion Nutraveda IPO
- Issue price
- ₹129
- Listing price
- ₹191
- +48.06%
- Current price
- ₹348.8
- +170.39%
- Subscribed
- 1.77x
- Issue size
- —
- Listed on
- 4 Feb 2026
IPO timeline
- Opens28 JanWed
- Closes30 JanFri
- Allotment2 FebMon
- Refunds3 FebTue
- Demat credit3 FebTue
- Listing4 FebWed
Issue details
- Price band
- ₹122 – ₹129 per share
- Issue size
- —
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital only
- Face value
- ₹10 per share
- Lot size
- 1,000 shares
- Minimum investment
- ₹1,29,000
- Listing on
- BSE SME
- Exchange code
- ANL.BO · 7564
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹1,29,000 |
| Retail (Max) | 1 | 1,000 | ₹1,29,000 |
| HNI (Min) | 2 | 2,000 | ₹2,58,000 |
Reservation
- QIB
- 9,08,000 shares (49.78% of the Offer)
- NII
- 2,76,000 shares (15.13% of the Offer)
- Retail
- 6,40,000 shares (35.09% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 2 Feb 2026
- Refunds initiated
- 3 Feb 2026
- Shares credited to demat
- 3 Feb 2026
- Listing
- 4 Feb 2026
Grey market premium (GMP)
- Current GMP
- ₹65
- +50.00%
- Estimated listing price
- ₹194
- Issue price ₹129
- Highest
- ₹65
- 4 Feb
- Lowest
- ₹0
- 27 Jan
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 4 Feb 2026 | ₹65 | +50.00% | ₹194 |
| 3 Feb 2026 | ₹17 | +13.00% | ₹146 |
| 2 Feb 2026 | ₹6 | +5.00% | ₹135 |
| 1 Feb 2026 | ₹6 | +5.00% | ₹135 |
| 31 Jan 2026 | ₹6 | +5.00% | ₹135 |
| 30 Jan 2026 | ₹0 | — | ₹129 |
| 29 Jan 2026 | ₹0 | — | ₹129 |
| 28 Jan 2026 | ₹0 | — | ₹129 |
| 27 Jan 2026 | ₹0 | — | ₹129 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB1.01x
- NII (HNI)1.8x
- Retail2.19x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 3,64,000 | 3,67,000 | 1.01x |
| Non-Institutional Investors (NII) | 3,72,000 | 6,69,000 | 1.8x |
| Retail Individual Investors (RII) | 6,40,000 | 14,04,000 | 2.19x |
| Total | 13,76,000 | 24,40,000 | 1.77x |
Financials
- P/E Ratio
- 20.02
- EPS (₹)
- 6.44
- RoCE
- 36.98%
- RoNW
- 48.85%
- PAT Margin
- 16.33%
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Accretion Nutraveda This IPO | — | 20.02 | 48.85% | 16.33% | 1.77x | +48.06% |
| Hannah Joseph Hospital SME · listed 1 Feb 2026 | — | 15.52 | 14.74% | 9.30% | 1.51x | -7.14% |
| KRM Ayurveda SME · listed 27 Jan 2026 | — | 23.73 | 67.86% | 15.80% | 74.43x | +27.48% |
| Modern Diagnostic & Research Centre SME · listed 7 Jan 2026 | — | 11.33 | 43.27% | 11.51% | 350.49x | 0.00% |
| Goldline Pharmaceutical SME · listed 19 May 2026 | ₹12 Cr | 13.93 | 27.37% | 10.09% | 781.85x | +38.95% |
| Himalaya Nutravedics India SME · listed 29 Sep 2026 | ₹26.5 Cr | 12.63 | 45.12% | 17.16% | 2.24x | +11.32% |
| Speciality Medicines SME · listed 30 Mar 2026 | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Accretion Nutraveda plans to use the money raised, as stated in the offer document.
- Capital expenditure towards purchase of new equipment/ machineries, etc. ₹2.7 Cr
- Capital expenditure towards upgradation of existing manufacturing facility ₹4.66 Cr
- Repayment/prepayme nt of certain borrowings availed by the Company ₹0.99 Cr
- Funding working capital requirements₹14.68 Cr
- General Corporate Purpose₹4.43 Cr
About Accretion Nutraveda
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Promoters and shareholding
Ankurkumar Shantilal Patel, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod, Mayur Popatlal Sojitra, Paraskumar Vinubhai Parmar and Vivek Ashok Kumar Patel
- Promoter holding, pre-issue
- 100%
- Promoter holding, post-issue
- 73.48%
Registrar, lead managers and documents
Lead manager
Company contact
27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand, Ahmedabad, Gujarat, 382213
+91- 9904366177
compliance@accretionnutraveda.comAccretion Nutraveda IPO: common questions
1.When does the Accretion Nutraveda IPO open and close?
The Accretion Nutraveda IPO opens on 28 Jan 2026 and closes on 30 Jan 2026.
2.What is the price band of the Accretion Nutraveda IPO?
The price band is ₹122 – ₹129 per share, with a lot size of 1,000 shares and a minimum investment of ₹1,29,000.
3.What is the GMP of the Accretion Nutraveda IPO?
The last reported grey market premium is ₹65 per share as of 04 Feb 2026, 10:37 AM IST. GMP is unofficial and changes frequently.
4.When is the Accretion Nutraveda IPO allotment?
The basis of allotment is expected on 2 Feb 2026. Allotment status can be checked with the registrar, KFin Technologies Limited.
5.When will the Accretion Nutraveda IPO list?
The shares listed on 4 Feb 2026 on BSE SME.
6.Who is the lead manager of the Accretion Nutraveda IPO?
The book running lead manager is Sobhagya Capital Options Pvt.Ltd., and the registrar is KFin Technologies Limited.
7.What will the money raised in the Accretion Nutraveda IPO be used for?
As stated in the offer document, the proceeds are for: Capital expenditure towards purchase of new equipment/ machineries, etc. ; Capital expenditure towards upgradation of existing manufacturing facility ; Repayment/prepayme nt of certain borrowings availed by the Company ; Funding working capital requirements; General Corporate Purpose.
8.How can my company launch an IPO like Accretion Nutraveda?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393